Patients

A Different Approach to Treating Disease

We are committed to innovation and technological advancement to create new drugs that can help people lead better and more hopeful lives. We are dedicated to the discovery and development of novel, first-in-class antisense drugs to address significant unmet medical needs in a wide variety of diseases. We focus our efforts on developing antisense drugs to treat a broad range of diseases such as, cardiovascular, metabolic, severe and rare/neurodegenerative diseases and cancer.

We are dedicated to the pursuit of scientific excellence. With our expertise, our scientists can optimize the properties of our antisense drugs and efficiently screen many targets in parallel to carefully select the best drugs to move into development.

Clinical Trial Information

We have several different ongoing clinical trials we designed to evaluate our drugs in a variety of health conditions including cardiovascular, metabolic, ocular and severe and rare/neurodegenerative diseases and cancer.

If you would like more information about a trial or want to enroll in a trial, please visit www.clinicaltrials.gov. This government-sponsored Web site lists most ongoing trials including those for which enrollment is currently taking place. Information is searchable by company, by drug candidate, by specific indication and by disease area. For each trial, the investigator is named and enrollment information is provided if appropriate.

Information can also be obtained by leaving a message on the following Isis toll-free number: 1-800-679-ISIS (4747) or by sending us an e-mail at info@isisph.com. These latter two channels are most appropriate if you'd like to speak with one of our clinical operations professionals about qualifying as a site or about supplying external services and support for clinical trials.

ALS Clinical Trial Informational Webcast

Wednesday, March 2, 2011 at 12:00 p.m. ET / 9 a.m. PT

A panel of investigators conducted an informational discussion about ALS clinical trials and a new investigational drug, ISIS-SOD1_Rx, which we are currently evaluating in patients with familial ALS due to mutations in SOD1. This archived webcast and presented slides are available to interested parties and can be accessed by clicking here.

The webcast features Merit Cudkowicz, M.D., Co-Chair of the Northeast ALS Consortium and a Professor of Neurology at the Massachusetts General Hospital of Harvard Medical School and Timothy Miller, M.D., Ph.D., Assistant Professor of Neurology at Washington University School of Medicine and Director of the Christopher Wells Hobler Laboratory for ALS Research at the Hope Center for Neurological Disorders.